美国的医疗机构建议不提供公共资金用于lecanab, 这种阿尔茨海默病药物可使早期的疾病减缓27%, 但成本高,风险高,有效性不尽相同. Canada’s drug agency recommends against public funding for lecanamab, an Alzheimer’s drug that slows early-stage disease by 27% but has high costs, risks, and variable effectiveness.

加拿大药品管理局建议不要公开资助lecanamab，这是一种新型阿尔茨海默病药物，通过靶向脑淀粉样蛋白积累，能减缓早期患者27%的病情进展。 Canada’s drug agency has recommended against publicly funding lecanamab, a new Alzheimer’s drug that slows disease progression by 27% in early-stage patients by targeting brain amyloid buildup. 这种药物是二十年来首款针对根本原因而非仅治症状的药物，需要频繁输液和核磁共振成像，年费用高达32,000美元，且存在罕见但严重的风险，如脑出血。 The drug, the first in two decades to address a root cause rather than just symptoms, requires frequent infusions and MRIs, costs up to $32,000 annually, and carries rare but serious risks like brain bleeds. 虽然专家们认为这是一个大有希望的步骤,但他们指出,效益有限,效力不一,特别是在妇女方面。 While experts call it a promising step, they note limited benefits and variable effectiveness, particularly in women. 这项裁决反映了联合王国和欧洲的裁决,可能会限制许多加拿大人,特别是没有私人保险的加拿大人获得保险,尽管它有可能扩大某些人的独立性。 The decision, mirroring rulings in the UK and Europe, may restrict access for many Canadians, especially those without private insurance, despite its potential to extend independence for some.